In The News
Judge worries compensation for axed Qantas ground crew ‘going off into the never never’
Coles, Woolworths hit with class actions over discount claims
ASIC seeks $20M penalty against Kraken crypto exchange
Parties race to settle Exactech joint implant class action
Judge balks at idea government could represent Robodebt class action members
ASIC sets sights on cost of living pressures in 2025 enforcement agenda
ACCC worried Cleanaway’s $110M Citywide tie-up may trash competition
Barristers acting on instructions from solicitor to be exempt from AML/CTF regime
ASIC slams ‘false’ premise of payday lender BSF’s appeal
Uber accused of refusing rides for blind passenger at Melbourne Airport
Please login to bookmarkClose

German drug company Fresenius Kadi has resolved a patent case brought by Korean drug company Samsung Bioepis over a biosimilar of top selling arthritis drug Humira.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?
Lost your password?

Contact us to enquire about group subscriptions.
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au